Zymeworks (ZYME) said Monday that new preclinical data for its experimental respiratory inflammation drug ZW1528 has shown positive results.
The drug targets two proteins involved in inflammation and blocks their signals to reduce immune responses, the company said.
In lab studies, ZW1528 worked well at stopping inflammation in immune cells taken from chronic obstructive pulmonary disease patients and also showed strong results in animal tests involving lung inflammation caused by dust mites, it added.
The drug remained stable at high concentrations, supporting the option of administering it through subcutaneous injection, according to the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。